2017-10-31T18:28:45-05:00 2016-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2016-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2063810883 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 C STEPHEN CORDIAL CHIEF FINANCIAL OFFICER 2063810883 2017-10-27 1 JANE M SEARING P00000565 4254544919 2017-10-30 65.158.230.202 2017-10-27 16:56:32 PD P D3602557FBBC398886185FEEA8787C976E007265 C070BA3AF7F6D7D87E83B9D9DF9412DF7C2C6F3F 2016 2021-01-29 14:40:06Z STEVEN R REED PHD 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 22177082 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF POVERTY. 11 8 157 8 0 0 19664811 10066730 6098639 9598506 857163 64522 1678789 1008787 28299402 20738545 14000 346425 0 0 10818103 11827460 0 0 82987 14273737 12892271 25105840 25066156 3193562 -4327611 37205100 32396570 21319603 20931895 15885497 11464675 X AS A "NONPROFIT BIOTECH," IDRI COMBINES THE HIGH-QUALITY SCIENCE OF A RESEARCH ORGANIZATION WITH THE PRODUCT DEVELOPMENT CAPABILITIES OF A BIOTECH COMPANY TO CREATE NEW DIAGNOSTICS, DRUGS AND VACCINES FOR INFECTIOUS DISEASES AND IMPROVE THE HEALTH OF THE WORLD. 0 0 9389250 305973 4139621 VACCINE RESEARCH - ONE OF THE GREATEST TRIUMPHS OF PUBLIC HEALTH, VACCINES HAVE BEEN USED FOR DECADES TO BOOST IMMUNITY AND PROTECT AGAINST SERIOUS DISEASES. IDRI SCIENTISTS ARE DEVELOPING INNOVATIVE VACCINES AGAINST DEADLY INFECTIOUS DISEASES SUCH AS TUBERCULOSIS, LEISHMANIASIS, AND LEPROSY, AS WELL AS NEWLY EMERGING THREATS INCLUDING ZIKA AND CHIKUNGUNYA. THE GOAL OF IDRI'S VACCINE WORK IS TO PRODUCE SAFE, EFFECTIVE AND LOW-COST VACCINES AND TO TRANSFER VACCINE TECHNOLOGY AND EXPERTISE TO DEVELOPING COUNTRIES SO THAT VACCINES CAN BE DEVELOPED QUICKLY WHEN DISEASE OUTBREAKS OCCUR. IDRI'S LEADING TUBERCULOSIS VACCINE CANDIDATE (ID93 + GLA-SE) HAS MOVED SUCCESSFULLY THROUGH EARLY STAGE CLINICAL TRIALS IN THE U.S. AND SOUTH AFRICA AND IN IS NOW IN A PHASE 2A CLINICAL TRIAL IN SOUTH AFRICA TO ASSESS THE ABILITY TO REDUCE TB RECURRENCE AFTER TREATMENT WAS RECENTLY COMPLETED. IDRI IS ALSO READYING FOR A CLINICAL TRIAL OF ITS LEPROSY VACCINE CANDIDATE. 2885483 2266943 ADJUVANT RESEARCH - ADJUVANTS ARE SUBSTANCES ADDED TO VACCINES THAT ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. THEY PROVIDE A KEY BENEFIT TO VACCINE DEVELOPMENT BY: IMPROVING IMMUNE RESPONSE, BROADENING VACCINE PROTECTION AND REDUCING THE AMOUNT OF VACCINE NEEDED.IDRI IS A WORLD LEADER IN ADJUVANT DEVELOPMENT AND HAS DEVELOPED MULTIPLE ADJUVANT FORMULATIONS. IN ADDITION TO VACCINES THAT IDRI IS DEVELOPING FOR TUBERCULOSIS, LEPROSY AND LEISHMANIASIS, IDRI SCIENTISTS ARE ALSO WORKING WITH COLLABORATORS TO PROVIDE ADJUVANTS FOR VACCINES BEING DEVELOPED IN VARIOUS DISEASE AREAS, INCLUDING MALARIA, HIV/AIDS, ZIKA AND PANDEMIC FLU. IN ADDITION, IDRI HAS TRANSFERRED ITS ADJUVANT TECHNOLOGIES TO ROMANIA, BRAZIL, SOUTH AFRICA AND INDIA, WHERE IDRI SCIENTISTS TEACH SCIENTISTS AND ENGINEERS HOW TO MANUFACTURE ADJUVANTS FOR THEIR OWN VACCINES. 4782787 14965 263035 TUBERCULOSIS DRUG DISCOVERY - IDRI'S TUBERCULOSIS DRUG DISCOVERY GROUP IS FOCUSED ON DISCOVERING AND DEVELOPING NOVEL DRUGS THAT ARE EFFECTIVE AT CURING DRUG SENSITIVE AND DRUG RESISTANT TB WITH THE ADDED GOAL OF SHORTENING THE TIME IT TAKES TO CURE DISEASE. TO DATE, SCIENTISTS AT IDRI HAVE SCREENED MORE THAN HALF A MILLION COMPOUNDS, CONTINUING THE IDENTIFICATION OF NEW LEADS AND DRUG TARGETS TO COMBAT TB.IDRI IS A FOUNDING MEMBER OF THE LILLY TB DRUG DISCOVERY INITIATIVE - HEADQUARTERED AT IDRI - AND THE TB DRUG ACCELERATOR (TBDA). THE LILLY INITIATIVE IS A UNIQUE PUBLIC-PRIVATE PARTNERSHIP WITH ELI LILLY AND COMPANY AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), PART OF THE NATIONAL INSTITUTES OF HEALTH (NIH), WITH A FOCUS ON THE DISCOVERY OF NEW ANTI-TUBERCULOSIS DRUGS. THE TBDA WAS FOUNDED AS A PARTNERSHIP OF SEVEN PHARMACEUTICAL COMPANIES AND FIVE OTHER ORGANIZATIONS, FUNDED IN PART BY THE BILL & MELINDA GATES FOUNDATION, TO TARGET THE DISCOVERY OF NEW TB DRUGS BY COLLABORATING ON EARLY-STAGE DRUG DISCOVERY FOR TUBERCULOSIS. 815397 1846459 MANUFACTURING - ONCE A VACCINE CANDIDATE HAS BEEN IDENTIFIED IN THE RESEARCH LAB, THE NEXT CHALLENGE IS TO APPLY THAT DISCOVERY TO THE CLINICAL SETTING. A NECESSARY PART OF THIS TRANSITION IS TO PRODUCE VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. IDRI HAS DEVELOPED THE TYPE OF MANUFACTURING CAPABILITY REQUIRED TO MOVE A VACCINE FROM LATE STAGE RESEARCH TO EARLY CLINICAL STUDIES. 1335401 25487 1082448 OTHER ACTIVITIES - IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL CONNECTIONS, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 2150798 25487 2928907 19208318 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 32 0 1 157 1 0 1 SF 0 0 0 0 0 0 0 0 X 11 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 0 X X C STEPHEN CORDIAL 2068586053 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 BRUCE CARTER PHD CHAIRMAN 5.00 0.00 X X 0 0 0 C STEPHEN CORDIAL MBA CFO/TREASURER 20.00 0.50 X X 92224 0 0 ERIK IVERSON JD LLM PRES. OF BUS & OPS/SECRETARY 5.00 1.00 X X 152998 0 14444 NORMAN BAYLOR PHD DIRECTOR 1.00 0.00 X 0 0 0 GAIL CASSEL PHD DIRECTOR 1.00 0.00 X 0 0 0 MICHEL DEWILDE PHD DIRECTOR 2.00 0.00 X 0 0 0 CHRIS HENTSCHEL PHD DIRECTOR 1.00 0.00 X 0 0 0 FRANKLYN PRENDERGAST MD PHD DIRECTOR 2.00 0.00 X 0 0 0 MASSIMO RADAELLI PHD DIRECTOR 2.00 0.00 X 0 0 0 STEVEN REED PHD PRESIDENT & CEO/DIRECTOR 40.00 1.00 X X 402622 0 19079 KARI STOEVER DIRECTOR 1.00 0.00 X 0 0 0 ROBERT LIN VP, FINANCE THRU 07/16 40.00 0.00 X 105837 0 14243 DOUGLAS BRADLEY GENERAL COUNSEL & SECRETARY 40.00 0.00 X 194086 0 13008 ANNA MARIE BECKMANN PHD SVP, PRODUCT DEV & REGULATORY 40.00 0.00 X 194666 0 23831 TANYA PARISH PHD SVP, DRUG DISCOVERY 40.00 0.00 X 173099 0 6968 DARRICK CARTER VP, ADJUVANT TECHNOLOGY 20.00 0.00 X 185872 0 1272 WINSTON WICOMB PHD DIRECTOR, VIVARIUM 40.00 0.00 X 165453 0 18153 KIM CLARY VP, ALLIANCE MANAGEMENT 40.00 0.00 X 148852 0 22602 JOSHUA ODINGO PHD DIRECTOR, CHEMISTRY 40.00 0.00 X 144389 0 20852 LEE SCHOENTRUP DIRECTOR, COMMUNICATIONS 40.00 0.00 X 138371 0 5559 2098469 0 160011 24 0 1 0 MORRISON & FOERSTER LLP PO BOX 742335 LOS ANGELES CA 90074 LEGAL SERVICES 510898 UNIVERSITY OF IOWA - CBB 2501 CROSSPARK RD STE C100 CORALVILLE IA 52241 RESEARCH 464088 JUBILANT CHEMSYS LTD B-34 SECTOR-58 NODIA IN RESEARCH 398440 TRICLINIUM CLINICAL TRIAL PM 135 WEST ST SANDOWN JOHANNESBURG SF 2196 RESEARCH 251187 TASK FOUNDATION NPC 1 DELANGE STREET BELLVILLE SF RESEARCH 176712 10 8678260 1388470 10066730 SERVICES AND CONTRACTS 541700 8623506 8623506 LICENSING 541700 975000 975000 9598506 3059 3059 1000571 1000571 1500000 1438537 61463 61463 61463 STORAGE FEES 900099 7803 7803 REIMBURSEMENTS 900099 413 413 8216 20738545 9598506 0 1073309 310938 310938 35487 35487 1407105 821815 558196 27094 8263346 6583562 1657862 21922 257385 214394 42104 887 1135884 898872 231967 5045 763740 588459 171443 3838 542943 16207 526736 92998 16500 76498 2092366 1853799 238455 112 10879 10588 291 397887 109471 288289 127 276507 43377 233130 506371 506371 2704512 2183280 516040 5192 401773 354767 46989 17 88337 25790 62547 1557427 1350080 205320 2027 129402 129402 LAB SUPPLIES 2574548 2522579 51969 SUBCONTRACTS 906236 906236 REPAIRS & MAINTENANCE 441251 342885 98366 168834 29820 122579 16435 25066156 19208318 5774851 82987 4140713 3431008 4571109 3136852 11327238 7207488 1582284 2270974 0 755515 183091 249908 25661802 10552461 15192870 15109341 95159 0 112636 235484 37205100 32396570 2767026 3117505 1715092 1932887 16837485 15881503 21319603 20931895 X 1213376 2283722 14672121 9180953 15885497 11464675 37205100 32396570 -4327611 -93211 0 X 0 1 X 1 1 1 X 20127852 11743860 9413720 19664811 10066730 71016973 20127852 11743860 9413720 19664811 10066730 71016973 19760707 51256266 896761 683996 727807 1672937 1003630 4985131 500 11373 8216 20089 76022193 22382521 0.67420 0.64810 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2013 AMOUNT: $ 500. REIMBURSEMENTS - 2016 AMOUNT: $ 413. STORAGE - 2016 AMOUNT: $ 7,803. CURRENCY EXCHANGE - 2015 AMOUNT: $ 11,373. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15203205 3800801 11402404 8599430 6751660 1847770 1859167 1859167 15109341 DEFERRED RENT 15881503 15881503 0 SOUTH ASIA 0 0 PROGRAM SERVICES RESEARCH 416786 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES RESEARCH 26303 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH 127912 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES RESEARCH 25208 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES RESEARCH 729465 SOUTH ASIA 0 0 PROGRAM SERVICES GRANTMAKING 25487 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES GRANTMAKING 10000 SUB-SAHARAN AFRICA 0 0 PROGRAM RELATED INVESTMENT PROGRAM RELATED INVESTMENTS 235484 0 0 0 0 0 0 1596645 0 1596645 EAST ASIA AND THE PACIFIC RESEARCH 25487 WIRE TRANSFER SOUTH ASIA RESEARCH 10000 WIRE TRANSFER 2 0 0 0 1 0 0 0 PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON ACCRUAL BASIS OF ACCOUNTING. 1 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES 5601 FISHERS LANE MSC 9804 BETHESDA MD 20892 520858115 GOVERNMENT 229965 N/A N/A RESEARCH JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 40000 N/A N/A RESEARCH UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 501(C)(3) 40973 N/A N/A RESEARCH 3 0 PART I, LINE 2: ALL PAYMENTS MADE FOR PROGRAM SERVICES WITHIN THE U.S. ARE BASED ON LEGAL AGREEMENTS BETWEEN IDRI AND THE PARTY RECEIVING PAYMENT. THESE AGREEMENTS INCLUDE REQUIREMENTS FOR BOTH PROGRESS AND FINANCIAL REPORTING BASED ON TIME PERIODS OR MILESTONE ACHIEVEMENTS. REPORTS ARE REVIEWED BY SCIENTIFIC AND ADMINISTRATIVE STAFF TO ENSURE THAT THE GOALS OF THE AGREEMENT AND ANY SPECIFIC FINANCIAL RESTRICTIONS ARE BEING MET BEFORE FURTHER PAYMENT IS MADE. MOST AGREEMENTS ALSO CONTAIN A CLAUSE GIVING IDRI THE RIGHT TO AUDIT FINANCIAL RECORDS OF THE PARTY IF NEEDED. X X X 0 0 0 1 0 0 0 0 0 ERIK IVERSON JD LLM PRES. OF BUS & OPS/SECRETARY 152998 0 0 0 0 0 6180 0 8264 0 167442 0 0 0 STEVEN REED PHD PRESIDENT & CEO/DIRECTOR 402622 0 0 0 0 0 6938 0 12141 0 421701 0 0 0 DOUGLAS BRADLEY GENERAL COUNSEL & SECRETARY 194086 0 0 0 0 0 7800 0 5208 0 207094 0 0 0 ANNA MARIE BECKMANN PHD SVP, PRODUCT DEV & REGULATORY 194666 0 0 0 0 0 15930 0 7901 0 218497 0 0 0 TANYA PARISH PHD SVP, DRUG DISCOVERY 173099 0 0 0 0 0 6968 0 0 0 180067 0 0 0 DARRICK CARTER VP, ADJUVANT TECHNOLOGY 185872 0 0 0 0 0 1272 0 0 0 187144 0 0 0 WINSTON WICOMB PHD DIRECTOR, VIVARIUM 165453 0 0 0 0 0 6718 0 11435 0 183606 0 0 0 KIM CLARY VP, ALLIANCE MANAGEMENT 148852 0 0 0 0 0 6073 0 16529 0 171454 0 0 0 JOSHUA ODINGO PHD DIRECTOR, CHEMISTRY 144389 0 0 0 0 0 4324 0 16528 0 165241 0 0 0 PART I, LINE 5 INVENTOR REVENUES SHARED WITH STEVEN REED AND OTHER PATENT HOLDERS WHEN INTELLECTUAL PROPERTY IS LICENSED. FORM 990, PART 1, LINE 6: THERE WERE EIGHT VOLUNTEER BOARD MEMBERS DURING THE YEAR. BOARD MEMBERS PARTICIPATE IN STRATEGIC PLANNING, EXECUTIVE LEADERSHIP RECRUITMENT AND SELECTION, INTELLECTUAL PROPERTY STRATEGY, AND IDENTIFICATION OF INSTITUTIONAL LIABILITY. THEY COME FROM A VARIETY OF BACKGROUNDS AND DEMONSTRATE FINANCIAL EXPERTISE, REAL ESTATE LEASING/PURCHASING EXPERTISE, BIO-MEDICAL NOT-FOR-PROFIT EXPERTISE, AND AN UNDERSTANDING OF BUSINESS AND BIOTECH LICENSING. FORM 990, PART VI, SECTION A, LINE 1 THE FOLLOWING VOTING MEMBERS OF THE BOARD ARE NOT INDEPENDENT: STEVE REED (PRESIDENT & CEO); ERIK IVERSON SERVED AS PRESIDENT OF BUSINESS AND OPERATIONS UNTIL JUNE, 2016; AND STEVE CORDIAL PROVIDED CONSULTING SERVICES AS ACTING CHIEF FINANCIAL OFFICER. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT COPY OF THE FORM 990 IS PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW. THE AUDIT COMMITTEE REVIEWS AND APPROVES THE FORM 990 ON BEHALF OF THE IDRI BOARD OF DIRECTORS. ALL BOARD MEMBERS RECEIVE A COPY OF THE FORM 990 PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EACH JANUARY, MEMBERS OF THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT ARE GIVEN A COPY OF THE CONFLICT OF INTEREST POLICY. THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT BY THE FIRST BOARD MEETING - USUALLY SOMETIME IN THE FIRST QUARTER. THE SENIOR VICE PRESIDENT OF OPERATIONS AND GENERAL COUNSEL REVIEWS THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE BOARD OF DIRECTORS. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE GROUP (MANAGEMENT TEAM OR BOARD) THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE CONDUCTED A FULL CEO PERFORMANCE AND COMPENSATION REVIEW, INITIATED IN MAY 2014, USING AN OUTSIDE INDEPENDENT CONSULTANT. THE REPORT IS IN THE BOARD MATERIALS AND IN THE PERSONNEL FILE. THE DECISIONS ARE IN THE COMPENSATION COMMITTEE NOTES. COMPARATIVE COMPENSATION INFORMATION WAS USED FROM THE CULPEPPER AND RADFORD PROFESSIONAL COMPENSATION FIRMS. THE BOARD CHAIR ALSO DOES AN ANNUAL REVIEW OF ALL OTHER OFFICERS AND KEY EMPLOYEES AND WORKS WITH THE HUMAN RESOURCES DEPARTMENT TO DETERMINE IF THE COMPENSATION IS ADEQUATE. IF AN ADJUSTMENT IS DEEMED NECESSARY, THE BOARD CHAIR CONVENES THE COMPENSATION COMMITTEE AND THE ADJUSTMENT IS ADDRESSED. THE BOARD CHAIR REPORTS BACK TO THE HUMAN RESOURCES DEPARTMENT WHO FOLLOWS THROUGH WITH THE COMMITTEE'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 THE IDRI AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE, WWW.IDRI.ORG. REQUESTS FOR OTHER INFORMATION SUCH AS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE HANDLED THROUGH OUR FINANCE DEPARTMENT AND INFORMATION IS DISTRIBUTED AS REQUESTED UNLESS CONFIDENTIAL IN NATURE. AFRIGEN BIOLOGICS (PTY) LTD 37 STRAND STREET CAPE TOWN WESTERN CAPE SF 8001 RESEARCH SF INFECTIOUS DISEASE RESEARCH INSTITUTE C -385330 264664 0.51000 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 AFRIGEN BIOLOGICS (PTY) LTD D 238258 COST